RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model.

RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Abstract Text:

Seiji Mabuchi,Deborah A Altomare,Mitchell Cheung,Lili Zhang,Poulikos I Poulikakos,Harvey H Hensley,Russell J Schilder,Robert F Ozols,Joseph R Testa,

PURPOSE: mTOR (mammalian target of rapamycin) plays a central role in regulating cell growth and cell cycle progression and is regarded as a promising therapeutic target. We examined whether mTOR inhibition by RAD001 (everolimus) is therapeutically efficacious in the treatment of ovarian cancer as a single agent and in combination with cisplatin. EXPERIMENTAL DESIGN: Using four human ovarian cancer cell lines, we determined the effect of RAD001 by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, Western blot, and apoptosis assays. We evaluated the association between phospho-AKT/mTOR activity and RAD001 sensitivity. We also determined the effect of RAD001 on tumor growth and malignancy using mice inoculated with human ovarian cancer cells. RESULTS: RAD001 markedly inhibited cell proliferation of human ovarian carcinoma cells with high AKT activity (OVCAR10 and SKOV-3), but the effect was minimal in cells with low AKT activity (OVCAR4 and OVCAR5). Sensitivity to RAD001 was independent of p53 expression. RAD001 inhibited the phosphorylation of downstream 4E-BP1 and p70S6 kinase and attenuated the expression of Myc. RAD001 also attenuated the expression of HIF-1 alpha and vascular endothelial growth factor, important factors in angiogenesis and tumor invasiveness. RAD001 enhanced cisplatin-induced apoptosis in cells with high AKT/mTOR activity, with minimal effect in cells with low AKT-mTOR activity. Mouse xenografts of SKOV-3 cells revealed that RAD001 inhibits tumor growth, angiogenesis, and i.p. dissemination and ascites production and prolongs survival. Moreover, treatment with RAD001 significantly enhanced the therapeutic efficacy of cisplatin in vivo. CONCLUSION: These results indicate that RAD001 could have therapeutic efficacy in human ovarian cancers with hyperactivated AKT/mTOR signaling.

RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Publishing Authors By Initials

S Mabuchi,DA Altomare,M Cheung,L Zhang,PI Poulikakos,HH Hensley,RJ Schilder,RF Ozols,JR Testa,

For similar organic chemicals: lactones: macrolides: sirolimus research abstracts see: organic chemicals: lactones: macrolides: sirolimus research

PUBMED ID PMID:

MEDLINE DATE:

RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Clinical cancer research : an official journal of

VOLUME: 13

Page Numbers: 4261-70

Journal Abbreviation: Clin. Cancer Res.

ISSN: 1078-0432

DAY: 15

MONTH: Jul

YEAR: 2007

RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9502500

RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Keywords Mesh Terms:

KEYWORDS: Sirolimus

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Information

Substance Name: Sirolimus

Registry Number: 53123-88-9

Grant and Affiliation Information for RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model.

AFFILIATION: Human Genetics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA.

Country: United States

AGENCY: United States NCI

GRANT: CA83638

ACRONYM: CA

MEDLINETA: Clin Cancer Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model Related Publications

• A novel recurrent chromosomal inversion implicates the homeobox gene Dlx5 in T-cell lymphomas from Lck-Akt2 transgenic mice.
• A simple approach to noninvasively identifying significant fibrosis in chronic hepatitis C patients in clinical practice.
• Assessing drug-likeness - what are we missing?
• Diabetes mellitus and impaired glucose tolerance in thalassaemia major: incidence, prevalence, risk factors and survival in patients followed in the Ferrara Center.
• Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions.
• Frequent activation of AKT2 kinase in human pancreatic carcinomas.
• M4 and M5 acute myeloid leukaemias display a high sensitivity to Bortezomib-mediated apoptosis.
• On the intracortical activity during recruiting responses: an analysis of laminar profiles before and after topical application of GABA to the cortex.
• Outcome assessment in patients with chronic obstructive rhinitis CO2 laser treated.
• Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis.
• RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer.
• RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model.
• Sexual health knowledge, attitudes and behaviours: variations among a religiously diverse sample of young people in London, UK.
• [A case of reconstruction by means of the Landolt-Hughes technic of the lower eyelid destroyed by a cutaneous epithelioma developed from atinic keratosis]
• [Addition of an oily phase in dehydration by means of evaporation]
• [Clinico-experimental research on a case of blepharochalasis]
• [Correction of hump nose associated with microgenia]
• [Epithelioma destruens of the lower eyelid. Reconstruction technic]
• [Facial plastic surgery. Our experience in 22 cases]
• [Fournier's fulminating gangrene of the genitalia (observations on 2 cases)]
• [Genetic studies of pathology of the ear, nose and throat.]
• [Lesions of the central nervous system in guinea pig with hypervitaminosis A.]
• [Not Available.]
• [Relations between stomatological disorders and cancer of the lip]
• [Rhinoplasty]
• [Sodium intake and interdialytic weight gain]
• [Substances active on the central nervous system. II. Derivatives of alpha-ethyl-alpha-phenyl-beta-hydroxypropionic acid & alpha-phenylbutyric acid.]
• [Test for evaluation of operative risk: Thorn test during veritol test.]
• [Water activity and food stability. I. Effects on viability of Saccharomyces cerevisiae cells (author's transl)]
• p21-activated kinase links Rac/Cdc42 signaling to merlin.